Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06097455

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma

First in Human, Pilot, Open-label, Prospective, Multicentre, Non-randomised Clinical Trial to Evaluate the Safety and Efficacy of ARI0003 (CART CD19/ CD269 Cells) in Patients With Relapsed/Refractory B-cell Aggressive Lymphoma

Status
Not Yet Recruiting
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Fundacion Clinic per a la Recerca Biomédica · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

ths study consist in testing a CAR T therapy (ARI0003 cells (antiCD19 and antiBCMA) in patients suffering relapsed NHL (that means that symptoms of NHL reappeared ) or refractory (that means that they did not respond to other treatments). This is a first in human study.

Conditions

Interventions

TypeNameDescription
GENETICARI0003Treatment with ARI0003 cells

Timeline

Start date
2024-01-15
Primary completion
2025-04-15
Completion
2027-01-15
First posted
2023-10-24
Last updated
2023-10-26

Locations

7 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT06097455. Inclusion in this directory is not an endorsement.